Skip to content

Pharminent

cropped-banner_frontpage_2026-07-11-2.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Policy / Pricing
  • How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan Market
  • Policy / Pricing

How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan Market

KFF Medicare

The private plans that offer the Medicare Part D benefit - stand-alone drug plans and Medicare Advantage drug plans - are increasingly are competing on uneven terms, in part because the payment system

Read full story

pharminent June 11, 2026 (Last updated: June 19, 2026)

KFF Medicare

The private plans that offer the Medicare Part D benefit – stand-alone drug plans and Medicare Advantage drug plans – are increasingly are competing on uneven terms, in part because the payment system

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Medicare Part D Enrollment, Premiums, and Cost Sharing in 2026
Next: Next Post

Related Stories

  • Policy / Pricing

Decoding Medicare Advantage Coding Intensity

pharminent July 1, 2026
  • Policy / Pricing

UK partners with Eli Lilly on obesity plan

pharminent June 29, 2026
  • Policy / Pricing

EFPIA report adds to pressures on EU drug pricing policy

pharminent June 24, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.